We’ve known for some time now that APS Type 1 patients are at an increased risk for severe COVID-19 complications. For this reason, we’ve all been particularly cautious and vigilant. And, APS Type 1 patients have been urged to get vaccinated.
Last week, the FDA and CDC recommended that people who are moderately to severely immunocompromised receive an additional dose of an mRNA vaccine (i.e., Pfizer-BioNTech or Moderna). You may have been asking yourself whether APS Type 1 qualifies as a moderate or severe immunocompromising condition. We sure were.
Today, we share with you a statement from Dr. Lionakis and his esteemed team at the NIH. In this statement, they recommend an additional dose of mRNA COVID-19 vaccine following an initial 2-dose primary mRNA COVID-19 vaccine series in patients with APECED. Click here to read the full statement.
The NIH wants to learn more about how our population is responding to the vaccines. If you’re interested in participating in NIH’s vaccine efficacy study, please contact Thomas DiMaggio for details. Also, if you need a letter from NIH to support your efforts to obtain the third vaccine shot, please contact Thomas.
Last, but not least, we encourage you to join us for our 4th International Symposium on APS Type 1. It’s a virtual event on September 18, 2021, 12 pm EDT – 4:00 pm EDT. Among others, Dr. Lionakis will be discussing more about vaccine efficacy in APS Type 1 patients. Click here to register.
We’re in this together. If we can help in any way, please let us know.